

How to bridge to transplant in relapsed ALL? Pro: CAR-T cells

Pei-hua(Peggy) Lu, MD

Lu Daopei Hospital

Since 2015 our institute has completed about 500 cases of CAR-T treatment on relapsed/refractory(R/R) B-ALL. 110 patients with R/R B-ALL were enrolled in this study (www.clinicaltrials.gov, NCT03173417). At D30, 102/110 (92.7%) patients achieved CR/CRi, and 96/106 (94.1%) achieved MRD-negative CR. After CAR-T treatment, majority patients underwent subsequent allo-HSCT in a median time of 63 days. OS and RFS were significantly better for patients who bridged into allo-HSCT than those who received CAR-T alone. The median recurrence time in the group without additional allo-HSCT was 90 days.

In addition, our two-year data of 84 patients after CAR-T treatment bridged into allo-HSCT indicated that the RFS in the MRD (-) CR group prior to allo-HSCT was much better than the MRD (+) CR group (80% vs 54%).

In conclusion, we recommend patients should conduct allo-HSCT as early as possible when MRD-negative CR was obtained after CAR-T.